Medtronic Structural Heart

Hunter and others like him chose Harmony™ TPV. Celebrating 1000+ Harmony TPV patients treated globally — and counting! See risk info bit.ly/3TOTJJU | Learn more: bit.ly/48k5bll #HarmonyTPV1000

Hear first-hand from Hunter, born with tetralogy of Fallot, about living with Harmony™ TPV for the last 2 years — and how he lives his life to the fullest. See risk info: bit.ly/48swJEU Learn more: bit.ly/478MlvZ #chd #HarmonyTPV1000

Innovation with a purpose - discover what Dr. @AshishPershad says about the Evolut™ FX platform and how design enhancements have led to exceptional performance. bit.ly/3RtfaOa People who know, think #EvolutFirst. | Risk Info: bit.ly/481BpBD

Why is early referral so important for symptomatic severe aortic stenosis? Hear from Dr. George Alravez and his #TAVR patient Julia. bit.ly/3RuInIf

Ready to increase your #TAVR skills? Join us on Medtronic Academy 2.0 for specialized training modules, live cases, and webinars. bit.ly/48fXXhS

Is Evolut™ TAVR your platform of choice? Learn why Dr. @RizikMd believes in the CoreValve™/Evolut platform's performance and outcomes. People who know, think #EvolutFirst. bit.ly/3uPGUVm | Risk Info: bit.ly/3Rjzxgz

Dr. Geoge Alravez restored Julia's health when he treated her with a supra-annular, self-expanding #TAVR for her symptomatic severe aortic stenosis. Discover why this technology is so transformative. bit.ly/47VNCI8 Risk Info: bit.ly/4aiz86B

Hear first-hand from Hunter, born with tetralogy of Fallot, about living with Harmony™ TPV for the last 2 years — and how he lives his life to the fullest. See risk info bit.ly/3RbOXU4 Learn more: bit.ly/3RFgS0f #chd #HarmonyTPV1000

Learn why Dr. Geoge Alravez treated Julia with a supra-annular, self-expanding #TAVR for her symptomatic severe aortic stenosis. Risk Info: bit.ly/4abx6oU Watch her full story: bit.ly/41aMcHf

Why did Dr. @AshishPershad switch to Evolut™ #TAVR? Patient outcomes. Hear about the results he has seen in his practice. bit.ly/47JPzap People who know, think #EvolutFirst. | Risk Info: bit.ly/46NoX7h

Evolut™ #TAVR is the ONLY platform to show numerically lower rate of death or disabling stroke in low-risk patients at 4 years than #SAVR. Discover the outcomes: bit.ly/4ab3MPx Risk info: bit.ly/4a8PEpN

John Rhodes M.D. reflects on recent 2-year Harmony™ TPV data and the positive outcomes seen in Hunter, one of the first to undergo the procedure. See risk info bit.ly/46Ew1Df Learn more: bit.ly/3t2BK7W #HarmonyTPV1000

Stay ahead of the curve and unlock new possibilities in #TAVR. Visit Medtronic Academy 2.0 today! bit.ly/3TaMs74

Staying up to date on clinical data is critical for treating low-risk #TAVR patients. Our late-breaking clinical trial at #TCT2023 shows the safety benefits of Evolut™ TAVR in low-risk patients: bit.ly/47HkLXR Risk info: bit.ly/47ZCb1Q

Dr. @RizikMd talks ease of use and deliverability with the EvolutTM FX system. Hear why his heart team fell in love with this #TAVR system. bit.ly/46A60VD People who know, think #EvolutFirst. | Risk Info: bit.ly/46EHxyg

Julia was dizzy; she couldn't walk or keep up with the kids at her daycare center in Laredo, TX. But she found hope when she met Dr. George Alvarez. Watch her full story: bit.ly/3QYPrg5

Two years ago, Hunter was one of the first Harmony™ TPV recipients. But today he's one of many patients living with this valve. Hear how his TPVR, time, & hard work has added up to health and happiness. See risk info bit.ly/3RizyTb | Learn more: bit.ly/46zSnWf

We're committed to providing the latest #TAVR data you need to make informed decisions for your patients. Download the 4-year outcomes from the Evolut Low Risk late-breaking clinical trial. bit.ly/3STgGLM Risk info: bit.ly/3SYdeiO

Find out what living life with Harmony™ TPV feels like for Hunter, 2 years post procedure. See risk info bit.ly/47Q5JPp Learn more: bit.ly/3SVq7uc #HarmonyTPV1000

Cusp overlap technique with the Evolut™ FX system drives predictable and proven outcomes. Dr. @AshishPershad shares his experience. bit.ly/3RdTyXd People who know, think #EvolutFirst. | Risk Info: bit.ly/40TLGNN